Chicago, USA-based generic injectables, biologicals and branded products company Meitheal Pharmaceuticals has acquired North America rights to Contempo (fosfomycin for injection) from Nabriva Therapeutics (Nasdaq: NBRV).
Contempo is a novel, intravenous (IV), broad spectrum antibiotic with demonstrated activity against most multi-drug resistant (MDR) strains that cause complicated urinary tract infections (cUTI), noted Meitheal, which is part of Nanjing King-Friend Biochemical Pharmaceutical.
“The strategic addition of Contempo to our robust product portfolio provides us with a novel therapeutic with the potential to address a significant unmet need around increasing antibiotic resistance,” said Tom Shea, chief executive of Meitheal.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze